STOCK TITAN
  1. Home
  2. News
  3. NTLA

Intellia Therapeutics Inc - NTLA STOCK NEWS

Welcome to our dedicated news page for Intellia Therapeutics (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intellia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intellia Therapeutics's position in the market.

News
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Rhea-AI Summary
Intellia Therapeutics, Inc. announces the dosing of the first patient in the global pivotal Phase 3 MAGNITUDE trial of NTLA-2001, an in vivo CRISPR-based therapy for transthyretin amyloidosis. Positive Phase 1 results showed deep and durable reductions in the TTR protein. The trial aims to evaluate efficacy and safety in patients with cardiomyopathy, potentially revolutionizing treatment for ATTR amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
clinical trial
-
News
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) reported operational highlights and financial results for Q4 2023, ending the year with approximately $1.0 billion in cash. They are on track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis and plan to initiate the Phase 3 study of NTLA-2002 for HAE in 2H24. Intellia aims to present new clinical data in 2024 from ongoing studies and expand development of in vivo CRISPR-based therapies beyond the liver, collaborating with ReCode for cystic fibrosis treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
earnings
-
News
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Rhea-AI Summary
Intellia Therapeutics (NTLA) and ReCode Therapeutics announce a strategic collaboration to develop novel genomic medicines for treating cystic fibrosis. The collaboration combines Intellia's CRISPR-based platform with ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery to target disease-causing gene mutations in the lung. Intellia will focus on editing strategy design, while ReCode will lead preclinical and clinical development and worldwide commercialization. The partnership aims to provide life-changing therapies for CF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
News
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) to announce Q4 and full-year 2023 financial results and operational highlights on February 22, 2024. The conference call will focus on their CRISPR-based therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
earnings
-
News
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced positive interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002, an investigational in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). The data revealed a 95% mean reduction in monthly HAE attack rate after a single dose of NTLA-2002, with 9 out of 10 patients remaining completely attack-free during the 16-week primary observation period. The results were published in the New England Journal of Medicine, reinforcing the potential of NTLA-2002 to eliminate angioedema attacks in people living with HAE. This marks a significant milestone in the development of revolutionary CRISPR-based therapies for rare genetic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
clinical trial
-
News
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
Rhea-AI Summary
Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced its strategic priorities through 2026 and key anticipated 2024 milestones. The company ended 2023 in a strong financial position with approximately $1.0 billion in cash and is on track to dose the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024. Intellia aims to transform the lives of patients and bring forth a new era in medicine by advancing its pipeline and platform innovations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
News
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced that the European Commission has granted orphan drug designation to NTLA-2002, an in vivo CRISPR-based investigational therapy for the treatment of hereditary angioedema (HAE). The orphan drug designation provides regulatory, financial, and commercial incentives to develop therapies for rare diseases. Intellia has received five special regulatory designations for NTLA-2002, indicating significant progress in the development of potential one-time treatment for people with HAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.09%
Tags
clinical trial
-
News
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received FDA clearance for NTLA-2001, the first in vivo CRISPR candidate to enter late-stage clinical development. The company plans to initiate the MAGNITUDE pivotal Phase 3 trial for patients with ATTR amyloidosis with cardiomyopathy by year-end. Clinical data showed consistent, deep, and durable serum TTR reduction after a single dose of NTLA-2001, with over 90% median serum TTR reduction. The company also reported a strong financial position with $992.5 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.27%
Tags
earnings
-
News
Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
Rhea-AI Summary
Intellia Therapeutics presents positive interim results from its Phase 1 study of NTLA-2001, an investigational CRISPR-based therapy for ATTR amyloidosis. The study shows consistent and deep reductions in serum TTR levels with a single dose of NTLA-2001. The 55 mg dose has been selected for further evaluation in a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
clinical trial
News
Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
Rhea-AI Summary
Intellia Therapeutics announces upcoming events in November: presentation of NTLA-2001 clinical data at the 4th International ATTR Amyloidosis Meeting and Q3 earnings webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences earnings clinical trial
Stock NTLA logo
Intellia Therapeutics Inc

Nasdaq:NTLA

NTLA Rankings

#1878 Ranked by Market Cap
#4821 Ranked by Stock Gains
N/A Ranked by Dividends

NTLA Stock Data

2.33B
94.53M
1.33%
87.42%
15.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About NTLA

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the